Managing Clinical and Cost Outcomes in Multiple Sclerosis:
Utilizing Data to Make Informed Decisions in Managed Care

A continuing medical education activity sponsored by NAMCP and AAMCN

This webinar series will provide critical updates on the advances in the management of MS

These are archives of live webinars held between November 19 to December 1, 2020.
If you participated in any of the live webinars, you are not eligible to
claim credit from the archive of that webinar.

By clicking on each of the titles, you will be able to participate in each part.
It is not required that you participate in all 3 or in order.

This activity is valid from January 1, 2021 to January 1, 2023

This series is supported by educational grants from
Biogen, Novartis Pharmaceuticals Corporation and Sanofi Genzyme

 Audience: This activity is intended for healthcare professionals practicing in managed care environments.

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

Description:
Multiple Sclerosis (MS) is a chronic progressive disease. It is the most common neurological cause of disability among young adults, with a prevalence of approximately one million cases throughout the United States. Although there is still no cure for MS, many advances in MS treatment have arrived in recent years, allowing patients to manage these symptoms and improve their quality of life. Effective and timely treatment of MS can greatly improve the quality of life in MS patients. With the advancement and complexity of different treatment options, including therapies that have recently become available, managed care professionals are being challenged to make informed decisions in their organizations and provide the correct treatment options that are available to patients.

A Closer Look into the Latest Data in the Treatment of Multiple Sclerosis: Utilizing Recent Evidence to Make Informed Decisions

1. Assess the impact of multiple sclerosis (MS) on a patient's quality of life and the burden to the healthcare system
2. Identify key indicators of MS to improve early diagnosis and initiation of treatment for MS
3. Analyze updated clinical data on the efficacy, safety, and dosing/administration of current and emerging therapies and their effect on staging and sequencing
4. Examine recent data related to available and investigational S1P therapies for the treatment of progressive forms of MS
5. Explore the emerging role of anti-CD20 monoclonal antibodies in the management of relapsing MS

Comparative Effectiveness and Payer-Provider Coordination in Multiple Sclerosis: What Does Managed Care Need to Know About New and Emerging Therapeutics?

1. Discuss key economic challenges surrounding management of patients with multiple sclerosis (MS) and the need for more optimal medical intervention to reduce healthcare costs
2. Explore the evolving role of new and emerging CD20-directed and S1P therapeutics in the management of MS, including managed care considerations around these therapies
3. Employ treatment optimization approaches to balance costs with improved outcomes in MS management
4. Integrate utilization management and benefit design strategies for MS therapies to enhance clinical and economic outcomes for patients with MS
5. Identify practices that managed care professionals can take to help improve outcomes, mitigate disease progression and ensure appropriate and timely access to disease-modifying therapies for MS

Improving Patient Adherence and Quality of Life in Multiple Sclerosis: Strategies for Managing Adverse Events Associated with New and Emerging Therapies

1. Examine challenges to patient adherence, dosing and quality of life in multiple sclerosis and adverse event management
2. Review strategies to monitor and manage adverse events associated with newer therapies, including S1P therapies and anti-CD-20 monoclonal antibodies, in MS in order to improve patient adherence and quality of life
3. Explore the role of subcutaneous administration methods in new and emerging therapies in MS
4. Identify and develop strategies to overcome potential barriers that affect timely access of MS disease-modifying therapies (DMTs) for patients through managed care organizations